CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
| Company Name: |
CRISPR Therapeutics AG |
| Website: |
www.crisprtx.com |
| Sector: |
Biotechnology |
| Number of ETFs Holding CRSP: |
24 |
| Total Market Value Held by ETFs: |
$591.94M |
| Total Market Capitalization: |
$4.71B |
| % of Market Cap. Held by ETFs: |
12.56% |
|
|
April 17, 2024 • 11:59 PM Eastern
Buy (2.83 out of 4)
100th percentile
|
|
Free CRSP Email Alerts:
